Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension of Ebronucimab (AK102) in Hypercholesterolemia
NCT04173403Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Nov 2019
- Primary completion
- Feb 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ebronucimab in hypercholesterolemia, sponsored by Akeso, Inc.. Started Nov 2019; status: completed.
02
Drugs
ebronucimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04173403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04173403.